NAMS

Business Context and Reporting Period

NewAmsterdam Pharma Company N.V. (NAMS) is a late-stage biopharmaceutical company focused on developing obicetrapib, an oral CETP inhibitor for lowering LDL-C. This Form 10-Q covers the quarterly period ended March 31, 2025. The company has no approved products and generates revenue solely from a license agreement with Menarini Group.

Key Financial Metrics

Note: The company reported a net loss per share of $(0.34) for Q1 2025 compared to $(1.06) for Q1 2024.

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss decreased by approximately $54.2 million compared to Q1 2024. This improvement was primarily driven by significant non-cash gains from changes in the fair value of derivative warrant liabilities ($13.8 million gain vs. $30.2 million loss) and earnout liabilities ($4.0 million gain vs. $8.7 million loss), as well as increased interest income ($7.4 million vs. $3.1 million).
• Operating Expenses: Total operating expenses increased by $15.0 million. SG&A expenses rose by $12.7 million (88% increase), largely due to higher personnel costs driven by share-based compensation and commercial preparation activities. R&D expenses increased by $2.3 million, offset by an $8.1 million decrease in clinical expenses due to the completion of several Phase 3 trials in late 2024.
• Revenue Growth: Revenue increased by $1.6 million (113%), attributed to the recognition of the first annual development cost contribution from the Menarini license agreement.
• Derivative Liability Settlement: The derivative earnout liability of $44.8 million recorded at year-end 2024 was fully settled in Q1 2025 upon the achievement of a milestone, resulting in the issuance of 1.74 million ordinary shares.

Guidance, Outlook, and Risks

• Clinical Progress: The company announced late-breaking data from the BROADWAY and TANDEM Phase 3 studies presented in May 2025. It is currently conducting the PREVAIL cardiovascular outcomes trial (CVOT).
• Liquidity: As of March 31, 2025, the company held $748.4 million in cash and cash equivalents, plus $60.1 million in marketable securities. Management believes this is sufficient to fund operations for the foreseeable future, though additional financing may be required to achieve long-term goals.
• Commercialization: The company plans to commercialize obicetrapib in the U.S. independently and relies on its partner Menarini for commercialization in certain European territories.
• Key Risks:
  • Regulatory Approval: No products are approved; success depends on FDA/EMA approval of obicetrapib.
  • Capital Requirements: Continued significant losses are expected; failure to raise additional capital could force delays in development.
  • Market Volatility: The company is no longer an "emerging growth company" as of December 31, 2024, leading to increased compliance costs.
  • Partnership Dependence: Reliance on Menarini for European commercialization and third-party CMOs/CROs for manufacturing and trials.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $808.5 million in liquid assets against the projected burn rate for the ongoing PREVAIL CVOT and commercial launch preparations.
• Menarini Agreement: Confirm the status of the second annual development cost contribution and the timeline for potential milestone payments.
• Derivative Liabilities: Monitor the fair value of remaining warrant liabilities ($23.5 million), which fluctuate with the company's stock price and impact reported net income.
• Share-Based Compensation: Review the $15.2 million in share-based compensation expense for Q1 2025 and its impact on future dilution and cash flow.
• Regulatory Milestones: Track the specific endpoints and data readouts from the PREVAIL trial, as these are critical for regulatory submission and commercial viability.